Johnson Matthey
Siegfried Holding AG
Pfizer
Sanofi S.A.
Novartis AG,
Bristol-Myers Squibb
Boehringer Ingelheim GmbH
GlaxoSmithKline
Albany Molecular Research Inc.
Bachem Holding AG
PCAS
Patheon N.V.
AstraZeneca
Johnson & Johnson
Merck & Co, Inc.
BASF SE
Catalent Inc.
Teva Pharmaceuticals
Roche
Cambrex Corporation
GILEAD Science Inc.
地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋（中国、日本、韓国、インド、東南アジア）
南アメリカ（ブラジル、アルゼンチン、コロンビアなど）
中東およびアフリカ（サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL SMALL MOLECULE ACTIVE PHARMACEUTICAL INGREDIENT INDUSTRY
2.1 Summary about Small Molecule Active Pharmaceutical Ingredient Industry
2.2 Small Molecule Active Pharmaceutical Ingredient Market Trends
2.2.1 Small Molecule Active Pharmaceutical Ingredient Production & Consumption Trends
2.2.2 Small Molecule Active Pharmaceutical Ingredient Demand Structure Trends
2.3 Small Molecule Active Pharmaceutical Ingredient Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Standard API
4.2.2 High Potency API
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Cardiovascular Diseases
4.3.2 Respiratory Disorders
4.3.3 Infectious Diseases
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Standard API
5.2.2 High Potency API
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Cardiovascular Diseases
5.3.2 Respiratory Disorders
5.3.3 Infectious Diseases
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Standard API
6.2.2 High Potency API
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Cardiovascular Diseases
6.3.2 Respiratory Disorders
6.3.3 Infectious Diseases
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Standard API
7.2.2 High Potency API
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Cardiovascular Diseases
7.3.2 Respiratory Disorders
7.3.3 Infectious Diseases
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Standard API
8.2.2 High Potency API
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Cardiovascular Diseases
8.3.2 Respiratory Disorders
8.3.3 Infectious Diseases
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Standard API
9.2.2 High Potency API
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Cardiovascular Diseases
9.3.2 Respiratory Disorders
9.3.3 Infectious Diseases
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Johnson Matthey
10.1.2 Siegfried Holding AG
10.1.3 Pfizer
10.1.4 Sanofi S.A.
10.1.5 Novartis AG,
10.1.6 Bristol-Myers Squibb
10.1.7 Boehringer Ingelheim GmbH
10.1.8 GlaxoSmithKline
10.1.9 Albany Molecular Research Inc.
10.1.10 Bachem Holding AG
10.1.11 PCAS
10.1.12 Patheon N.V.
10.1.13 AstraZeneca
10.1.14 Johnson & Johnson
10.1.15 Merck & Co, Inc.
10.1.16 BASF SE
10.1.17 Catalent Inc.
10.1.18 Teva Pharmaceuticals
10.1.19 Roche
10.1.20 Cambrex Corporation
10.1.21 GILEAD Science Inc.
10.2 Small Molecule Active Pharmaceutical Ingredient Sales Date of Major Players (2017-2020e)
10.2.1 Johnson Matthey
10.2.2 Siegfried Holding AG
10.2.3 Pfizer
10.2.4 Sanofi S.A.
10.2.5 Novartis AG,
10.2.6 Bristol-Myers Squibb
10.2.7 Boehringer Ingelheim GmbH
10.2.8 GlaxoSmithKline
10.2.9 Albany Molecular Research Inc.
10.2.10 Bachem Holding AG
10.2.11 PCAS
10.2.12 Patheon N.V.
10.2.13 AstraZeneca
10.2.14 Johnson & Johnson
10.2.15 Merck & Co, Inc.
10.2.16 BASF SE
10.2.17 Catalent Inc.
10.2.18 Teva Pharmaceuticals
10.2.19 Roche
10.2.20 Cambrex Corporation
10.2.21 GILEAD Science Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
